Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Curis, Inc.
Memorial Sloan Kettering Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
University of Texas Southwestern Medical Center
Wake Forest University Health Sciences
BeOne Medicines
Dren Bio
Recursion Pharmaceuticals Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
VA Office of Research and Development
Deciphera Pharmaceuticals, LLC
National Institutes of Health Clinical Center (CC)
Instituto de Investigación Biomédica de Salamanca
Miltenyi Biomedicine GmbH
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Hangzhou Hanx Biopharmaceuticals, Ltd.
University of Texas Southwestern Medical Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Avenzo Therapeutics, Inc.
Takeda
Novartis
Novartis
Ottimo Pharma Limited
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Anova Innovation Limited
Institute of Hematology and Blood Transfusion, Czech Republic
Hoosier Cancer Research Network
Arvinas Inc.
BioInvent International AB
AVM Biotechnology Inc
New York Medical College
BeOne Medicines
Tango Therapeutics, Inc.
ImmunityBio, Inc.
University of Alabama at Birmingham
University of Alabama at Birmingham
Washington University School of Medicine
Centre Antoine Lacassagne
Lyell Immunopharma, Inc.